Vol. 14. Núm. 19.
Páginas 1125-1130 (Octubre 2024)

Actualización
Tratamiento no farmacológico de la diabetes mellitus tipo 2. Cirugía de la obesidad. Nuevas estrategias terapéuticas

Nonpharmacological treatment of type 2 diabetes mellitus. Obesity surgery. New treatment strategies

J.B. Quiñones SilvaaA. Bayona CebadaabcdH.F. Escobar-MorrealeacdL. Nattero Chávezabc
Doi : https://10.1016/j.med.2024.10.012
Opciones
Resumen

La incidencia y prevalencia de la diabetes mellitus tipo 2 (DM2) y la obesidad están aumentando globalmente y se encuentran estrechamente interrelacionadas. La cirugía de la obesidad (cirugía metabólica) es una herramienta válida y eficaz para la reducción ponderal y la remisión de la DM2. Esta actualización describe las diferentes técnicas quirúrgicas de la cirugía de la obesidad. También se enumera la evidencia disponible sobre los estudios observacionales y los ensayos clínicos que han dado soporte a las recomendaciones de esta intervención en pacientes con DM2 y obesidad. Por último se describen nuevas estrategias terapéuticas emergentes relacionadas con péptidos involucrados con el efecto incretina (GLP-1, GIP y glucagón) y los inhibidores de los receptores de glucosa (SGLT).

Palabras clave
Diabetes mellitus tipo 2
Obesidad
Cirugía bariátrica
Inhibidores de SGLT-2
Agonistas GLP-1
Abstract

The incidence and prevalence of type 2 diabetes mellitus (DM2) and obesity are increasing globally and are closely interrelated. Obesity surgery (metabolic surgery) is a valid, effective tool for weight reduction and remission of DM2. This update describes the different surgical techniques in obesity surgery. It also lists the available evidence on the observational studies and clinical trials that have supported recommendations for this intervention in patients with DM2 and obesity. Lastly, emerging treatment strategies related to peptides involved with the incretin effect (GLP-1, GIP, and glucagon) and glucose receptor inhibitors (SGLT) are described.

Keywords
Type 2 diabetes mellitus
Obesity
Bariatric surgery
SGLT-2 inhibitors
GLP-1 agonists

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
World
202410150440168888
202410150440168889
Health Organization. https://www.who.int/es/news-room/fact-sheets/detail/diabetes. 2023. Diabetes.
[2]
D. Aune
2024101504401688810
2024101504401688811
, T. Norat, M. Leitzmann, S. Tonstad, L.J. Vatten.
Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis.
Eur J Epidemiol., (2015), 30 pp. 529-542
[3]
S.H. Ley
2024101504401688812
2024101504401688813
, O. Hamdy, V. Mohan, F.B. Hu.
Prevention and management of type 2 diabetes: dietary components and nutritional strategies.
Lancet., (2014), 383 pp. 1999-2007
[4]
S. Taheri
2024101504401688814
2024101504401688815
, H. Zaghloul, O. Chagoury, S. Elhadad, S.H. Ahmed, N. El Khatib, et al.
Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.
Lancet Diabetes Endocrinol., (2020), 8 pp. 477-489
[5]
B. Cresci
2024101504401688816
2024101504401688817
, C. Cosentino, M. Monami, E. Mannucci.
Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials.
Diabetes Obes Metab., (2020), 22 pp. 1378-1387
[6]
J.B. Buse
2024101504401688818
2024101504401688819
, S. Caprio, W.T. Cefalu, A. Ceriello, S. Del Prato, S.E. Inzucchi, et al.
How do we define cure of diabetes?.
Diabetes Care., (2009), 32 pp. 2133-2135
[7]
A.C. Celio
2024101504401688820
2024101504401688821
, W.J. Pories.
A history of bariatric surgery: The maturation of a medical discipline.
Surg Clin North Am., (2016), 96 pp. 655-667
[8]
A.H. Affinati
2024101504401688822
2024101504401688823
, N.H. Esfandiari, E.A. Oral, A.T. Kraftson.
Bariatric surgery in the treatment of type 2 diabetes.
Curr Diab Rep., (2019), 19 pp. 156
[9]
L.T. DeWind
2024101504401688824
2024101504401688825
, J.H. Payne.
Intestinal bypass surgery for morbid obesity: long-term results.
[10]
W.J. Pories
2024101504401688826
2024101504401688827
.
Bariatric surgery: risks and rewards.
J Clin Endocrinol Metab., (2008), 93 pp. S89-S96
[11]
C.L. McBride
2024101504401688828
2024101504401688829
, V. Kothari.
Evolution of laparoscopic adjustable gastric banding.
Surg Clin North Am [Internet]., (2011), 91 pp. 1239-1247
[12]
G. Alfredo
2024101504401688830
2024101504401688831
, M. Roberta, C. Massimiliano, L. Michele, B. Nicola, R. Adriano.
Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study.
Surg Obes Relat Dis., (2014), 10 pp. 307-311
[13]
H. Buchwald
2024101504401688832
2024101504401688833
.
The evolution of metabolic/bariatric surgery.
Obes Surg., (2014), 24 pp. 1126-1135
[14]
M.A. Nauck
2024101504401688834
2024101504401688835
, J.J. Meier.
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
Lancet Diabetes Endocrinol., (2016), 4 pp. 525-536
[15]
L. Sjöström
2024101504401688836
2024101504401688837
, A.K. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, et al.
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
New Engl J Med., (2004), 351 pp. 2683-2693
[16]
P.R. Schauer
2024101504401688838
2024101504401688839
, B. Burguera, S. Ikramuddin, D. Cottam, W. Gourash, G. Hamad, et al.
Effect of laparoscopic roux-en y gastric bypass on type 2 diabetes mellitus.
[17]
D.J. Pournaras
2024101504401688840
2024101504401688841
, A. Osborne, S.C. Hawkins, R.P. Vincent, D. Mahon, P. Ewings, et al.
Remission of type 2 diabetes after gastric bypass and banding: Mechanisms and 2 year outcomes.
Ann Surg., (2010), 252 pp. 966-971
[18]
G.S. Jakobsen
2024101504401688842
2024101504401688843
, M.C. Småstuen, R. Sandbu, N. Nordstrand, D. Hofsø, M. Lindberg, et al.
Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities.
[19]
L.R. Madsen
2024101504401688844
2024101504401688845
, L.M. Baggesen, B. Richelsen, R.W. Thomsen.
Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study.
Diabetología., (2019), 62 pp. 611-620
[20]
A.P. Courcoulas
2024101504401688846
2024101504401688847
, M.E. Patti, B. Hu, D.E. Arterburn, D.C. Simonson, W.F. Gourash, et al.
Long-term outcomes of medical management vs bariatric surgery in type 2 Diabetes.
JAMA., (2024), 331 pp. 654-664
[21]
H. Elrick
2024101504401688848
2024101504401688849
, L. Stimmler, C.J. Hlad, Y. Arai.
Plasma insulin response to oral and intravenous glucose administration.
J Clin Endocrinol Metab., (1964), 24 pp. 1076-1082
[22]
R. Yin
2024101504401688850
2024101504401688851
, Y. Xu, X. Wang, L. Yang, D. Zhao.
Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment.
Molecules., (2022), 27 pp. 3055
[23]
M.A. Nauck
2024101504401688852
2024101504401688853
, J.J. Meier.
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
Lancet Diabetes Endocrinol., (2016), 4 pp. 525-536
[24]
T. Min
2024101504401688854
2024101504401688855
, S.C. Bain.
The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials.
Diabetes Ther., (2021), 12 pp. 143-157
[25]
S. Urva
2024101504401688856
2024101504401688857
, T. Coskun, M.T. Loh, Y. Du, M.K. Thomas, S. Gurbuz, et al.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet., (2022), 400 pp. 1869-1881
[26]
J. Rosenstock
2024101504401688858
2024101504401688859
, J. Frias, A.M. Jastreboff, Y. Du, J. Lou, S. Gurbuz, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet., (2023), 402 pp. 529-544
[27]
E. Pratt
2024101504401688860
2024101504401688861
, X. Ma, R. Liu, D. Robins, T. Coskun, K.W. Sloop, et al.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab., (2023), 25 pp. 2642-2649
[28]
M.G. Posch
2024101504401688862
2024101504401688863
, N. Walther, E. Ferrannini, D.R. Powell, P. Banks, S. Wason, et al.
Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: A randomized, double-blind study.
Diabetes Care., (2022), 45 pp. 2118
[29]
D.L. Bhatt
2024101504401688864
2024101504401688865
, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire, et al.
Sotagliflozin in patients with diabetes and recent worsening heart failure.
N Engl J Med., (2021), 384 pp. 117-128
[30]
D.L. Bhatt
2024101504401688866
2024101504401688867
, M. Szarek, B. Pitt, C.P. Cannon, L.A. Leiter, D.K. McGuire, et al.
Sotagliflozin in patients with diabetes and chronic kidney disease.
N Engl J Med., (2021), 384 pp. 129-139